This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
and you are
over 18
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.

Provided treatments

  • Drug: 80 mg ixekizumab Dosing Regimen
  • Drug: 50 mg etanercept
  • Drug: Placebo

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01597245. The sponsor of the trial is Eli Lilly and Company and it is looking for 1224 volunteers for the current phase.
Official trial title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis